Ginkgo Bioworks Netherlands B.V.

Ginkgo Bioworks Netherlands B.V. is a biotechnology firm that specializes in biological engineering products and custom microbes for various markets. The company designs, engineers, develops, tests, and licenses organisms, focusing on discovering molecules in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it provides probiotic bacteria for infection protection and generates libraries of molecules. Ginkgo serves several markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. Known as The Organism Company and headquartered in Boston, Ginkgo leverages biology as a manufacturing technology. Its advanced cell programming platform enables the development of biotechnology solutions across diverse sectors, such as food, fragrance, and pharmaceuticals. Ginkgo offers solutions for gene therapy, cell therapy, RNA therapeutics, biocatalysts, and molecular diagnostics, among others. It also addresses biological threats for federal agencies in agriculture, defense, energy, healthcare, and more. The company provides custom R&D solutions, packaged services, and industrial enzymes, focusing on sustainable ingredients and chemicals. Ginkgo has invested over $1 billion in its R&D platform, which combines automated labs, AI tools, and scientific expertise. It is currently collaborating with HaDEA on a consortium project worth up to €24 million to develop next-generation ‘Agnostic Diagnostics' for respiratory viruses at the point of care. Ginkgo invites partnerships to expedite research with tailored solutions.